/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BioAtla Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.82 0.06(6%) BCAB at 04 Dec 2025 04:26 PM Biotechnology
Lowest Today 0.76
Highest Today 0.8554
Today’s Open 0.78
Prev. Close 0.7794
52 Week High 1.72
52 Week Low 0.24
Day’s Range: Low 0.76 High 0.8554
52-Week Range: Low 0.24 High 1.72
1 day return -
1 Week return -8.18
1 month return +23.33
3 month return +67.62
6 month return +77.85
1 year return -48.7
3 year return -92.05
5 year return -97.28
10 year return -

Institutional Holdings

Vanguard Group Inc 3.04

TANG CAPITAL MANAGEMENT LLC 2.34

Vanguard Total Stock Mkt Idx Inv 2.03

Renaissance Technologies Corp 1.28

SQUAD Aguja Opportunities I 1.28

Deutsche Bank AG 0.89

Geode Capital Management, LLC 0.84

BlackRock Inc 0.82

Vanguard Institutional Extnd Mkt Idx Tr 0.64

Morgan Stanley - Brokerage Accounts 0.54

Fidelity Extended Market Index 0.45

ADAR1 Capital Management LLC 0.29

State Street Corp 0.26

Xtrackers MSCI World Swap ETF 1C 0.25

Northern Trust Corp 0.17

Two Sigma Investments LLC 0.14

Extended Equity Market Fund K 0.14

Fidelity Total Market Index 0.14

Marshall Wace Asset Management Ltd 0.14

Susquehanna International Group, LLP 0.13

Fidelity Series Total Market Index 0.12

Magnus Financial Group LLC 0.08

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Mccormack Advisors International 0.08

Spartan Extended Market Index Pool F 0.07

Alpha Cubed Investments LLC 0.07

NT Ext Equity Mkt Idx Fd - NL 0.05

National Asset Management Inc 0.05

UBS Group AG 0.05

Vanguard Instl Ttl Stck Mkt Idx Tr 0.05

COLUMBIA ADVISORY PARTNERS LLC 0.04

Commonwealth Equity Services Inc 0.04

Spartan Total Market Index Pool G 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

Vanguard U.S. Eq Idx £ Acc 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

State St US Extended Mkt Indx NL Cl C 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Extended Equity Market Fund M 0.02

Market Status

Strong Buy: 2

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 45.82 M

PB Ratio 2.681

PE Ratio 0.0

Enterprise Value 44.51 M

Total Assets 52.42 M

Volume 804131

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:250000 0.3M, FY20:429000 0.4M, FY19:5200000 5.2M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:250000 0.3M, FY20:429000 0.4M, FY19:5200000 5.2M

Annual Net worth FY23:-124080000 -124.1M, FY22:-105283000 -105.3M, FY21:-95406000 -95.4M, FY20:-37241000 -37.2M, FY19:-31402000 -31.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:11000000 11.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-56000 -0.1M, Q2/2025:-567000 -0.6M, Q1/2025:-183000 -0.2M, Q3/2024:11000000 11.0M, Q2/2024:-229000 -0.2M

Quarterly Net worth Q3/2025:-15778000 -15.8M, Q2/2025:-18711000 -18.7M, Q1/2025:-15334000 -15.3M, Q3/2024:-10586000 -10.6M, Q2/2024:-21072000 -21.1M

Fund house & investment objective

Company Information BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 61

Industry Biotechnology

CEO Dr. Jay M. Short Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow